J.M.LANAO, S.ROMANO, M.M.FDEZ.DE GATTA, M.V.CALVO, D.CABALLERO, A.DOMÍNGUEZ-GIL.
Population Pharmacokinetics Of Amikacin In Hematologic Malignant Patients
|
Patrick Mismetti, Silvy Laporte, Pascal Girard, Hervé Decousus
Indirect Pharmacodynamic Model With Two Different Markers Of Oral Anticoagulant In Young Healthy Volunteers
|
D. Santos Buelga, G. Frutos, MJ Garcia, MJ Otero, A. Dominguez-Gil
Optimization Of A Population Pharmacokinetic Model Of Theophylline In Adult Patients
|
Taright N. (1), Mentré F. (1), Engrand P. (2), Loumaye E. (2), Trinchard-Lugan I. (2), Munafo A. (2).
Population Pharmacokinetics of Recombinant Human Luteinising Hormone in Patients
|
M.J. García, D. Santos Buelga, M.J. Otero, B. Blanco, A.C. Falcão, A. Domínguez-Gil
Therapeutic Drug Monitoring Of Antiepileptic Drugs; Can We Use TDM Data To Estimate Population Pharmacokinetic Parameters?
|
M. Van Guilder(1), R. Leary(2), A. Schumitzky(1), X.Wang(1), S. Vinks(3), and R. Jelliffe(1).
Nonlinear Nonparametric Population Modeling On A Supercomputer.
|
I.Meineke
Modelling interoccasion variability after repeated oral drug administration.
|
I. Nestorov, L. Aarons, M. Rowland
A population approach to the study of structure-pharmacokinetic relationships: An example with a homologous series of barbiturates
|
Y. Merlé, E. Schmautz, and A Mallet.
Assessment Of Two Strategies For Detecting Pharmacodynamic Interactions In The Context Of The NPMLApproach;
|
P. Noertersheuser, S. Ghani, S.Kreis
Evaluation of the dose / concentration / response relationship of an antithrombotic acting development drug, performed with NONMEM and P - PHARM
|
U. Wählby*, E. N. Jonsson and M. O. Karlsson
A Stepwise Procedure For Interindividual Variability Model Building
|
Williams P, Lane J., Capparelli E., Turkel C.
Computer Simulation: A Useful Tool for Trial Dosage Selection
|
GE Blakey, P McCormack, ADP Dean and N Entwistle
An Exploratory Population Pharmacokinetic Analysis Examining The Influence Of Demography and Co-Medication On The Plasma Clearance Of The Anti- Epileptic Remacemide.
|
S Chabaud, P Girard, P Nony , C. Laveille, JP Boissel.
PK-PD Model Of Ivabradine, A Bradycardic Agent, And Its Metabolite In Healthy Volunteers
|
Farkad Ezzet
Population Pharmacokinetics And Therapeutic Response Of Artemether Following Treatment Of Coartem In Malaria Patients
|
N. Frey (1), M. Dubard (1), J.M.A. Van Gerven (2), and R. Jochemsen (1)
Population pharmacokinetics/pharmacodynamics of rilmenidine in 27 hypertensive patients
|
P.McCormack, L. Aarons, N.Yeates, M. Nassim, J. Gardner and M. Russell
Pharmacokinetic and pharmacodynamics of AR-C69931MX a novel P2T antagonist in healthy male and female volunteers.
|
Nicolas Simon, Eliane Fuseau, Peter Daley-Yates
Fluticasone propionate pharmacokinetics in asthma patients when administered alone or in combination to salmeterol.
|
Georg Hempel, Mats O. Karlsson*, Dinesh P. de Alwis John McNay, Nathalie Toublanc and Hans G. Schaefer
Population PK/PD Modelling of 24h-Ambulatory Blood Pressure Data using NONMEM
|
L.Nguyen, P. Variol, B. Tranchand* and C. Puozzo.
Population pharmacokinetics of Navelbine: Model set up from phase I data and Validation of a limiting sampling strategy
|
M. Costa*, E. Berno#, G. P. Zara#, C. Della Pepa#, R. Canaparo, M. Eandi#
A Non-Parametric Population PK/PD Analysis Of Tolcapone To Predict L-Dopa Plasma Concentrations
|
P. Ghahramani, W.W. Yeo, G.T. Tucker
Use of NONMEM to determine the influence of CYP2D6 activity on the pharmacokinetics of amitriptyline and nortriptyline
|
